Cytokine– tag –
-
IV Exosome Therapy: Under Investigation for Cell Behavior Modulation and Anti-Inflammation, FDA Not Yet Approved
Sanger Wellness Center USA Overview Exosomes, tiny extracellular vesicles involved in intercellular communication, are being investigated for their potential to influence cell behavior, inflammatory pathways, tissue response, and recover... -
Commercial-Scale iPSC Cell Therapy: Advancements in Off-the-Shelf Treatments, Immunogenicity, and Cost Reduction are Key
The Medicine Maker UK Overview This article examines the challenges and technological advances in scaling induced pluripotent stem cell (iPSC) platforms for commercial cell therapies. It highlights the shift towards allogeneic, off-the-s... -
Moffitt Cancer Center’s Dr. Yvonne Chen Proposes Novel Strategies to Overcome Tumor Microenvironment Barriers in Solid Tumors with Logic-Gated CAR T-Cells
Moffitt Cancer Center USA Overview Dr. Yvonne Chen of Moffitt Cancer Center has discussed new strategies to enhance CAR-T cell therapy for solid tumors, focusing on precise targeting with logic-gated CAR-T cells and reprogramming the tum... -
Xilio Therapeutics Reports Q2 2026 Financial Results, Advances Tumor Microenvironment-Activated Immunotherapy Pipeline with Promising Early Clinical Data
GlobeNewswire USA Overview Xilio Therapeutics released its Q2 2026 financial results, reporting significant pipeline progress for its tumor microenvironment (TME)-activated immunotherapy candidates. Lead programs XTX101, XTX202, and XTX3... -
CEA-Targeted CAR-NK Cells Derived from iPSCs Demonstrate Potent Anti-Tumor Activity Against Colorectal Cancer
Frontiers in Immunology Unknown Overview A new study reports that chimeric antigen receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) exhibit potent anti-tumor activity against colorectal cancer. These CEA-target... -
Real-World Data Evaluates Incidence and Management of Cytokine Release Syndrome and Neurotoxicity Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel CAR-T Cell Therapy Across 87 U.S. Centers
PubMed (Center for International Blood and Marrow Transplant Research) USA Overview The Center for International Blood and Marrow Transplant Research (CIBMTR) conducted a real-world data analysis of 927 B-cell malignancy patients across ... -
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
Allogene’s Off-the-Shelf CAR T, Cema-Cel, Earns FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
Allogene Therapeutics, Inc. USA Overview Allogene Therapeutics has secured FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (... -
Hospital Capacity, Not Just Manufacturing, Identified as True Bottleneck for CAR-T Therapy Commercialization
Chivanta Unknown Overview The greatest challenge in commercializing CAR-T cell therapies is not solely manufacturing capacity but also the hospital infrastructure and the overall treatment process. Clinical operational bottlenecks, speci... -
NTHRYS Achieves 40% Cost Reduction in Dual Antigen CAR-T Manufacturing, Offers Off-the-Shelf NK Cell Expansion Services
NTHRYS International Overview NTHRYS has successfully reduced manufacturing costs for dual antigen CAR-T cell scale-up by 40% while accelerating time-to-clinic. Furthermore, the company now offers clinical-grade NK cell expansion and cry...
12